LENSAR Inc
NASDAQ:LNSR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.17
7.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
LENSAR Inc
LENSAR Inc
Total Liabilities & Equity
LENSAR Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LENSAR Inc
NASDAQ:LNSR
|
Total Liabilities & Equity
$69.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Liabilities & Equity
$57.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
16%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Liabilities & Equity
$38.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Liabilities & Equity
$43.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Liabilities & Equity
$73B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Liabilities & Equity
$17.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
LENSAR Inc
Glance View
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 110 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The company is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.
See Also
What is LENSAR Inc's Total Liabilities & Equity?
Total Liabilities & Equity
69.6m
USD
Based on the financial report for Dec 31, 2023, LENSAR Inc's Total Liabilities & Equity amounts to 69.6m USD.
What is LENSAR Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
19%
Over the last year, the Total Liabilities & Equity growth was 25%. The average annual Total Liabilities & Equity growth rates for LENSAR Inc have been -4% over the past three years , 19% over the past five years .
You don't have any saved screeners yet
